Xenetic Biosciences, Inc. (XBIO)

NASDAQ: XBIO · IEX Real-Time Price · USD
4.220
+0.110 (2.68%)
Jul 22, 2024, 11:24 AM EDT - Market open
2.68%
Market Cap 6.41M
Revenue (ttm) 2.44M
Net Income (ttm) -4.47M
Shares Out 1.54M
EPS (ttm) -2.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 509
Open 4.124
Previous Close 4.110
Day's Range 4.220 - 4.220
52-Week Range 2.870 - 5.970
Beta 2.30
Analysts n/a
Price Target n/a
Earnings Date Aug 9, 2024

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline in... [Read more]

Industry Biotechnology
Sector Healthcare
CEO James F. Parslow
Employees 4
Stock Exchange NASDAQ
Ticker Symbol XBIO
Full Company Profile

Financial Performance

In 2023, XBIO's revenue was $2.54 million, an increase of 48.80% compared to the previous year's $1.71 million. Losses were -$4.13 million, -36.90% less than in 2022.

Financial Statements

News

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of ...

2 months ago - Accesswire

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with...

4 months ago - Accesswire

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc...

6 months ago - Accesswire

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carci...

9 months ago - Accesswire

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Bioscience...

10 months ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech...

11 months ago - Accesswire

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic s...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutic...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors - Ended the quarter wit...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May ...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Ph...

1 year ago - Accesswire

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET - FRENCH...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 ...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology techn...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical com...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the ...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $13.8 million of...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer ...

Other symbols: VNRX
1 year ago - Accesswire

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology techno...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech...

2 years ago - Accesswire

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic Advancing lead DNase program towards Phase 1 study for...

2 years ago - Accesswire

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing ...

Other symbols: VNRX
2 years ago - Accesswire